Doubling up against prostate

Even before seeing the final efficacy results from an ongoing Phase II trial of its autologous vaccine against prostate specific antigen (PSA), Immuno-Designed Molecules S.A. has closed a deal to combine the vaccine with an antibody in development at Medarex Inc. The hope

Read the full 432 word article

How to gain access

Continue reading with a
two-week free trial.